文献速递乳房整形与再造显微修复重建

COX-2抑制剂与自体乳房重建术后游离皮瓣并发症:回顾性队列研究

Cyclooxygenase-2 inhibitors and free flap complications after autologous breast reconstruction: A retrospective cohort study.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2017-06-20

该回顾性队列研究比较了自体乳房重建术后使用COX-2抑制剂与NSAID的多模式镇痛方案,发现COX-2抑制剂组术后血肿再手术率显著低于NSAID组(3.1% vs 9.8%,p=0.02),而皮瓣丢失率无差异(2.3% vs 1.5%,p=0.63),提示COX-2抑制剂安全且不增加皮瓣失败风险。

要点

  • COX-2抑制剂组术后血肿再手术率显著低于NSAID组(3.1% vs 9.8%,p=0.02)。
  • 两组皮瓣丢失率无显著差异(2.3% vs 1.5%,p=0.63)。
  • COX-2抑制剂可作为游离皮瓣乳房重建术后多模式镇痛的安全选择。

核心结论

  • 使用COX-2抑制剂的多模式镇痛在游离皮瓣自体乳房重建中是安全的,不增加皮瓣失败率,且可能减少术后血肿风险。

研究设计与样本

  • 回顾性队列研究,比较NSAID时期(2007-2011年,132例单侧二次自体乳房重建)与COX-2抑制剂时期(2006年、2012-2014年,128例)的并发症。

主要发现

  • NSAID组术后血肿再手术13/132例(9.8%),COX-2抑制剂组4/128例(3.1%),差异有统计学意义(p=0.02)。
  • 皮瓣丢失率NSAID组2/132例(1.5%),COX-2抑制剂组3/128例(2.3%),无显著差异(p=0.63)。
  • 两组均无血栓栓塞并发症或胃肠道出血发生。

临床怎么用

  • 在自体乳房重建游离皮瓣术后,可考虑使用COX-2抑制剂作为多模式阿片节省镇痛的一部分,以降低血肿风险而不增加皮瓣失败。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A key component of modern analgesics is the use of multimodal opioid-sparing analgesia (MOSA). In the past, our analgesic regime after autologous breast reconstruction (ABR) included either NSAID or a selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 inhibitors are superior to NSAIDs because of the well-known side effects of NSAID treatment (bleeding/gastrointestinal ulcers). However, COX-2 inhibitors have been suggested to increase flap failure rates. We report our experience in using COX-2 inhibitors as part of our post-operative MOSA after ABR using free flaps. MATERIALS AND METHODS: A total of 132 unilateral secondary ABR were performed (DIEP or MS-TRAM) in the NSAID period (2007-2011) and 128 in the COX-2 inhibitor period (2006, 2012-2014). The same surgical team operated all patients. Data were collected prospectively and reviewed to compare the two periods, with special focus on reoperations due to bleeding/haematomas and flap thrombosis/failure. Comparisons between the COX-2 inhibitor and NSAID were made. RESULTS: Median age, ischaemia time, blood loss and operating time were similar in the two periods. Significantly, more patients were re-operated because of post-operative haematoma in the NSAID group (n = 13/132, 9.8%) than in the COX-2 inhibitor group (n = 4/128, 3.1%) (p = 0.02). We found no difference in flap loss rates between the NSAID (n = 2/132, 1.5%) and the COX-2 inhibitor groups (n = 3/128, 2.3%) (p = 0.63). No patients suffered from thromboembolic complications or gastrointestinal bleeding. CONCLUSIONS: Multimodal analgesia using a COX-2 inhibitor is safe in ABR with free flaps and does not increase flap failure. COX-2 inhibitors seem superior to NSAID with reduced risk of post-operative haematomas.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Bonde C, Khorasani H, Hoejvig J, et al. Cyclooxygenase-2 inhibitors and free flap complications after autologous breast reconstruction: A retrospective cohort study. J Plast Reconstr Aesthet Surg. 2017. PMID: 28822648. doi:10.1016/j.bjps.2017.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。